 |
44 Diseases |  |
3 Trials |
|
3 Trials |  |
52 News |  |
- | Trial completion date, Trial primary completion date: Pancreatic Clamp in NAFLD (clinicaltrials.gov) - Sep 19, 2024
P1, N=42, Recruiting, Sponsor: Columbia University
Trial completion date: Jan 2025 --> May 2025 | Trial primary completion date: Aug 2024 --> Mar 2025
- | Enrollment change: Pancreatic Clamp in NAFLD (clinicaltrials.gov) - Mar 19, 2024
P1, N=42, Recruiting, Sponsor: Columbia University
Trial completion date: Jan 2025 --> May 2025 | Trial primary completion date: Aug 2024 --> Mar 2025 N=20 --> 42
- | Norditropin (somatropin) / Novo Nordisk
Enrollment open, Enrollment change: Growth Hormone Replacement in Veterans With GWI and AGHD (GWIT) (clinicaltrials.gov) - Jan 16, 2024
P2, N=20, Recruiting, Sponsor: Baylor College of Medicine
N=20 --> 42 Not yet recruiting --> Recruiting | N=36 --> 20
- | New P3 trial: Randomized Clinical Trial of Two Different Initial Growth Hormone Doses in Children (clinicaltrials.gov) - Oct 25, 2023
P3, N=50, Recruiting, Sponsor: Northwell Health
- somatropin / Generic mfg.
Enrollment change: Evaluate the Efficacy and Safety Growth Hormone, Glutamine and Diet in Patients With Short Bowel Syndrome (SBS) (clinicaltrials.gov) - Jul 31, 2023
P4, N=5, Terminated, Sponsor: University of Nebraska
Not yet recruiting --> Recruiting | N=36 --> 20 N=30 --> 5
- | Enrollment open: Pancreatic Clamp in NAFLD (clinicaltrials.gov) - Jul 7, 2023
P1, N=20, Recruiting, Sponsor: Columbia University
N=30 --> 5 Not yet recruiting --> Recruiting
- | Enrollment open, Trial initiation date: Pancreatic Clamp in NAFLD (clinicaltrials.gov) - Mar 16, 2023
P1, N=20, Recruiting, Sponsor: Columbia University
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting | Initiation date: Feb 2023 --> Jun 2023
- | Norditropin (somatropin) / Novo Nordisk
Trial completion date, Trial primary completion date: Growth Hormone Replacement in Veterans With GWI and AGHD (GWIT) (clinicaltrials.gov) - Feb 16, 2023
P2, N=36, Not yet recruiting, Sponsor: Baylor College of Medicine
Not yet recruiting --> Recruiting | Initiation date: Feb 2023 --> Jun 2023 Trial completion date: Sep 2024 --> Sep 2025 | Trial primary completion date: May 2024 --> May 2025
- | New P1 trial: Pancreatic Clamp in NAFLD (clinicaltrials.gov) - Feb 13, 2023
P1, N=20, Recruiting, Sponsor: Columbia University
- | Norditropin (somatropin) / Novo Nordisk
Trial initiation date: Growth Hormone Replacement in Veterans With GWI and AGHD (GWIT) (clinicaltrials.gov) - Feb 8, 2023
P2, N=36, Not yet recruiting, Sponsor: Baylor College of Medicine
Trial completion date: Sep 2024 --> Sep 2025 | Trial primary completion date: May 2024 --> May 2025 Initiation date: Aug 2022 --> Jun 2023
- | Nutropin AQ (somatropin) / Ipsen, Roche
Trial completion: STARFISH: Study of Testosterone and rHGH in FSHD (clinicaltrials.gov) - Jun 9, 2022
P1, N=20, Completed, Sponsor: University of Rochester
Initiation date: Aug 2022 --> Jun 2023 Active, not recruiting --> Completed
- | Norditropin (somatropin) / Novo Nordisk
New P2 trial: Growth Hormone Replacement in Veterans With GWI and AGHD (GWIT) (clinicaltrials.gov) - May 1, 2022
P2, N=36, Not yet recruiting, Sponsor: Baylor College of Medicine
- | Journal: Lonapegsomatropin (Skytrofa) for growth hormone deficiency. (Pubmed Central) - Feb 23, 2022
Active, not recruiting --> Completed No abstract available
- | Nutropin AQ (somatropin) / Ipsen, Roche
Enrollment closed: STARFISH: Study of Testosterone and rHGH in FSHD (clinicaltrials.gov) - Sep 9, 2021
P1, N=20, Active, not recruiting, Sponsor: University of Rochester
No abstract available Recruiting --> Active, not recruiting
- | somatropin / Generic mfg.
Trial completion: Growth Hormone Therapy and Bone Quality in Pediatric Osteoporosis (clinicaltrials.gov) - Aug 31, 2021
P3, N=21, Completed, Sponsor: The Hospital for Sick Children
Recruiting --> Active, not recruiting Recruiting --> Completed
- Humatrope (somatropin) / BMS, Eli Lilly, Omnitrope (somatotropin) / Novartis
[VIRTUAL] The efficacy and safety of recombinant biosimilar growth hormone treatment in children with GHD and SGA: a Czech retrospective national longitudinal study () - Aug 27, 2021 - Abstract #ESPE2021ESPE_889;
The aim of our study is to assess height gain and safety of therapy with biosimilar rhGH (Omnitrope®, Sandoz) in Czech children with GHD and SGA over the first three years of treatment and to compare our data with longitudinal international study GeNeSIS Italian Cohort (Humatrope®, Eli Lilly). Our data confirm significant improvement of growth parameters and safety of therapy with biosimilar rhGH Omnitrope® in Czech children with GHD and SGA which is consistent with results from international database GeNeSIS study.
- | Nutropin AQ (somatropin) / Ipsen, Roche
Trial completion date, Trial primary completion date: STARFISH: Study of Testosterone and rHGH in FSHD (clinicaltrials.gov) - May 10, 2021
P1, N=20, Recruiting, Sponsor: University of Rochester
Our data confirm significant improvement of growth parameters and safety of therapy with biosimilar rhGH Omnitrope® in Czech children with GHD and SGA which is consistent with results from international database GeNeSIS study. Trial completion date: Apr 2021 --> Apr 2022 | Trial primary completion date: Apr 2021 --> Apr 2022
- | Humatrope (somatropin) / BMS, Eli Lilly
@LillyPad Humatrope Injection Shortage in Pakistan ? (Twitter) - Apr 17, 2021
- | somatropin / Generic mfg.
Trial termination: Growth Hormone and GnRH Agonist in Adolescents With Acquired Hypothyroidism (clinicaltrials.gov) - Oct 30, 2020
P4, N=16, Terminated, Sponsor: Baylor College of Medicine
Trial completion date: Apr 2021 --> Apr 2022 | Trial primary completion date: Apr 2021 --> Apr 2022 Completed --> Terminated
- | Nutropin AQ (somatropin) / Ipsen, Roche
Trial completion date, Trial primary completion date: STARFISH: Study of Testosterone and rHGH in FSHD (clinicaltrials.gov) - Apr 27, 2020
P1, N=20, Recruiting, Sponsor: University of Rochester
Completed --> Terminated Trial completion date: Jul 2020 --> Apr 2021 | Trial primary completion date: Jul 2020 --> Apr 2021
- | Trial completion date, Trial primary completion date: Human Growth Hormone Pre-treatment for 6 Weeks Prior to Ovulation Induction for IVF (clinicaltrials.gov) - Feb 18, 2020
P1/2, N=30, Enrolling by invitation, Sponsor: Center for Human Reproduction
Trial completion date: Jul 2020 --> Apr 2021 | Trial primary completion date: Jul 2020 --> Apr 2021 Trial completion date: Jun 2019 --> Jun 2022 | Trial primary completion date: Jun 2018 --> Jun 2021
- | Clinical data, Trial completion date, Trial termination: Assessment of the Treatment of Severely Burned With Anabolic Agents on Clinical Outcomes, Recovery and Rehabilitation (clinicaltrials.gov) - Nov 30, 2019
P2/3, N=1126, Terminated, Sponsor: The University of Texas Medical Branch, Galveston
Trial completion date: Sep 2018 --> Jul 2019 | Recruiting --> Terminated; At the request of the study site, this study has been closed and access to study-related data is unavailable. We are unable to submit the results-data.
- | Nutropin AQ (somatropin) / Ipsen, Roche
Trial initiation date: STARFISH: Study of Testosterone and rHGH in FSHD (clinicaltrials.gov) - Jan 9, 2018
P1, N=20, Recruiting, Sponsor: University of Rochester
We are unable to submit the results-data. Initiation date: Sep 2017 --> Dec 2017
- | Nutropin AQ (somatropin) / Ipsen, Roche
Enrollment open: STARFISH: Study of Testosterone and rHGH in FSHD (clinicaltrials.gov) - Aug 21, 2017
P1, N=20, Recruiting, Sponsor: University of Rochester
Initiation date: Sep 2017 --> Dec 2017 Not yet recruiting --> Recruiting
- | Trial primary completion date: Human Growth Hormone Pre-treatment for 6 Weeks Prior to Ovulation Induction for IVF (clinicaltrials.gov) - Jul 12, 2017
P1/2, N=30, Enrolling by invitation, Sponsor: Center for Human Reproduction
Not yet recruiting --> Recruiting Trial primary completion date: Jun 2017 --> Jun 2018
- | Trial completion: The Effects of Hormones in Growth Hormone-Treated Girls With Turner Syndrome (clinicaltrials.gov) - Jun 30, 2017
P2, N=80, Completed, Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Trial primary completion date: Jun 2017 --> Jun 2018 No longer recruiting --> Completed
- | Clinical data, Trial primary completion date: Assessment of the Treatment of Severely Burned With Anabolic Agents on Clinical Outcomes, Recovery and Rehabilitation (clinicaltrials.gov) - May 31, 2017
P2/3, N=1100, Recruiting, Sponsor: The University of Texas Medical Branch, Galveston
No longer recruiting --> Completed Trial primary completion date: Sep 2017 --> Sep 2018
- | somatropin / Generic mfg.
Trial completion: Growth Hormone Therapy in Osteogenesis Imperfecta (clinicaltrials.gov) - May 23, 2017
P3, N=52, Completed, Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Trial primary completion date: Sep 2017 --> Sep 2018 Active, not recruiting --> Completed
- | Nutropin AQ (somatropin) / Ipsen, Roche
New P1 trial: STARFISH: Study of Testosterone and rHGH in FSHD (clinicaltrials.gov) - Apr 20, 2017
P1, N=20, Not yet recruiting, Sponsor: University of Rochester
- somatropin / Generic mfg.
Trial primary completion date: Growth Hormone Therapy in Osteogenesis Imperfecta (clinicaltrials.gov) - Jul 19, 2016
P3, N=52, Active, not recruiting, Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Active, not recruiting --> Completed Trial primary completion date: Jun 2016 --> Mar 2017
- Trial primary completion date: Human Growth Hormone Pre-treatment for 6 Weeks Prior to Ovulation Induction for IVF (clinicaltrials.gov) - Jun 28, 2016
P1/2, N=30, Enrolling by invitation, Sponsor: Center for Human Reproduction
Trial primary completion date: Jun 2016 --> Mar 2017 Trial primary completion date: Jun 2016 --> Jun 2017
- | Clinical data, Enrollment change: Assessment of the Treatment of Severely Burned With Anabolic Agents on Clinical Outcomes, Recovery and Rehabilitation (clinicaltrials.gov) - Dec 5, 2015
P2/3, N=1100, Recruiting, Sponsor: The University of Texas Medical Branch, Galveston
Trial primary completion date: Jun 2016 --> Jun 2017 N=900 --> 1100
- ||| somatropin / Generic mfg.
Trial completion: GeNeSIS: Observational Study of Somatropin Treatment in Children (clinicaltrials.gov) - Oct 27, 2015
P=N/A, N=22929, Completed, Sponsor: Eli Lilly and Company
N=900 --> 1100 Active, not recruiting --> Completed
- |||| somatropin / Generic mfg.
Trial completion, Enrollment change: Long-Term Growth and Skeletal Effects of Early Growth Hormone Treatment in Turner Syndrome (clinicaltrials.gov) - Sep 26, 2015
P4, N=69, Completed, Sponsor: Eli Lilly and Company
Active, not recruiting --> Completed Recruiting --> Completed | N=88 --> 69
- | somatropin / Generic mfg.
Trial completion, Trial primary completion date: Growth Hormone and GnRH Agonist in Adolescents With Acquired Hypothyroidism (clinicaltrials.gov) - Sep 23, 2015
P4, N=21, Completed, Sponsor: Baylor College of Medicine
Recruiting --> Completed | N=88 --> 69 Recruiting --> Completed | Trial primary completion date: Mar 2012 --> Sep 2011
- ||||||| somatropin / Generic mfg.
Trial completion, Combination therapy: Phoenix: Somatropin + Leuprorelin vs Somatropin Alone in Pubertal Children With Idiopathic Short Stature (clinicaltrials.gov) - Aug 13, 2015
P3, N=94, Completed, Sponsor: Eli Lilly and Company
Recruiting --> Completed | Trial primary completion date: Mar 2012 --> Sep 2011 Active, not recruiting --> Completed
- somatropin / Generic mfg.
Trial primary completion date: Growth Hormone Therapy in Osteogenesis Imperfecta (clinicaltrials.gov) - Jul 9, 2015
P3, N=52, Active, not recruiting, Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Active, not recruiting --> Completed Trial primary completion date: Jun 2015 --> Jun 2016
- Enrollment open: Human Growth Hormone Pre-treatment for 6 Weeks Prior to Ovulation Induction for IVF (clinicaltrials.gov) - Jun 25, 2015
P1/2, N=30, Enrolling by invitation, Sponsor: Center for Human Reproduction
Trial primary completion date: Jun 2015 --> Jun 2016 Not yet recruiting --> Enrolling by invitation
- somatropin / Generic mfg.
Trial primary completion date: Growth Hormone Therapy in Osteogenesis Imperfecta (clinicaltrials.gov) - Mar 7, 2015
P3, N=52, Active, not recruiting, Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Not yet recruiting --> Enrolling by invitation Trial primary completion date: Mar 2014 --> Jun 2015
- New P1/2 trial: Human Growth Hormone Pre-treatment for 6 Weeks Prior to Ovulation Induction for IVF (clinicaltrials.gov) - Jul 1, 2014
P1/2, N=30, Not yet recruiting, Sponsor: Center for Human Reproduction
- || somatropin / Generic mfg.
Enrollment change: HypoCCS: A Prospective Observational Study of Effect of Somatropin on Growth Hormone Deficient Adults (clinicaltrials.gov) - Mar 24, 2014
P=N/A, N=10673, Completed, Sponsor: Eli Lilly and Company
Trial primary completion date: Mar 2014 --> Jun 2015 N=8000 --> 10673
- || somatropin / Generic mfg.
Enrollment closed: GeNeSIS: Observational Study of Somatropin Treatment in Children (clinicaltrials.gov) - Feb 16, 2014
P=N/A, N=23500, Active, not recruiting, Sponsor: Eli Lilly and Company
N=8000 --> 10673 Enrolling by invitation --> Active, not recruiting
- somatropin / Generic mfg.
Enrollment open: Growth Hormone Therapy and Bone Quality in Pediatric Osteoporosis (clinicaltrials.gov) - Sep 4, 2013
P3, N=28, Recruiting, Sponsor: The Hospital for Sick Children
Enrolling by invitation --> Active, not recruiting Not yet recruiting --> Recruiting
- | somatropin / Generic mfg.
Enrollment closed: Growth Hormone Therapy in Osteogenesis Imperfecta (clinicaltrials.gov) - Jul 15, 2013
P3, N=52, Active, not recruiting, Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- ||| somatropin / Generic mfg.
Trial completion: HypoCCS: A Prospective Observational Study of Effect of Somatropin on Growth Hormone Deficient Adults (clinicaltrials.gov) - Dec 5, 2012
P=N/A, N=10673, Completed, Sponsor: Eli Lilly and Company
Recruiting --> Active, not recruiting Enrolling by invitation --> Completed
- | Clinical data, Trial initiation date: Assessment of the Treatment of Severely Burned With Anabolic Agents on Clinical Outcomes, Recovery and Rehabilitation (clinicaltrials.gov) - Nov 12, 2012
P2/3, N=800, Recruiting, Sponsor: The University of Texas, Galveston
Enrolling by invitation --> Completed Initiation date: Jan 1998 --> Jan 2004